Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...
Bank of America Global Healthcare Conference 2026 May 13, 2026 2:20 PM EDTCompany ParticipantsDouglas Love - CEO, President ...
9d
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Claseprubart granted ...
Consolidated net revenue of € 713.4 million in the first quarter of 2026, +4.9% or +8.7% on a like-for-like basis(3) at constant exchange rates ...
The first quarter 2026 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be ...
MedPage Today on MSN
Cemdisiran siRNA therapy demonstrates efficacy in myasthenia gravis
Investigational treatment improves outcomes without complete complement blockade ...
In a double-blind, placebo-controlled phase 2 randomized clinical trial, vemircopan did not meet the predefined efficacy ...
May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain ...
What was once viewed as experimental is now entering a phase of operational maturity. The Turing Award recognition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results